Your Health, We Care
Strong CYP3A inhibitors: Concomitant use should be avoided; if coadministration is unavoidable, the dose of ponatinib should be reduced.
Strong CYP3A inducers: Concomitant use should be avoided.
FDA,2022.02
At present, the core objective of research related to ponatinib is to improve it···【more】
Release date：2026-01-21Recommended：20
Patients should maintain a written list of all prescription drugs, over-the-coun···【more】
Release date：2026-01-21Recommended：22
